losartan-potassium and Amnesia--Anterograde

losartan-potassium has been researched along with Amnesia--Anterograde* in 1 studies

Other Studies

1 other study(ies) available for losartan-potassium and Amnesia--Anterograde

Article	Year
Further improving the cognitive effect profile of electroconvulsive therapy (ECT): the case for studying carbamylated erythropoietin. Medical hypotheses, 2015, Volume: 84, Issue:3 Electroconvulsive therapy (ECT) remains the most effective acute treatment for severe depression and several other psychiatric illnesses. However, its use has been limited by concerns about cognitive adverse effects. ECT may cause temporary cognitive impairment in some patients, typically anterograde amnesia for 1-2 weeks after a course of treatment, and circumscribed retrograde amnesia. These cognitive effects largely disappear within days to weeks after treatment. Efforts to find a pharmacological agent to reduce the cognitive effects of ECT have largely been unsuccessful, with the possible exception of thyroid hormone. We review the literature on pharmacological attempts to attenuate ECT's cognitive effects, and propose a novel neuroprotective and neurotrophic agent, carbamylated erythropoietin (CEPO), for this indication. Topics: Amnesia, Anterograde; Cognition; Depression; Electroconvulsive Therapy; Erythropoietin; Humans; Models, Biological; Thyroid Hormones	2015

Article

Year

Further improving the cognitive effect profile of electroconvulsive therapy (ECT): the case for studying carbamylated erythropoietin.

Medical hypotheses, 2015, Volume: 84, Issue:3

Electroconvulsive therapy (ECT) remains the most effective acute treatment for severe depression and several other psychiatric illnesses. However, its use has been limited by concerns about cognitive adverse effects. ECT may cause temporary cognitive impairment in some patients, typically anterograde amnesia for 1-2 weeks after a course of treatment, and circumscribed retrograde amnesia. These cognitive effects largely disappear within days to weeks after treatment. Efforts to find a pharmacological agent to reduce the cognitive effects of ECT have largely been unsuccessful, with the possible exception of thyroid hormone. We review the literature on pharmacological attempts to attenuate ECT's cognitive effects, and propose a novel neuroprotective and neurotrophic agent, carbamylated erythropoietin (CEPO), for this indication.

Topics: Amnesia, Anterograde; Cognition; Depression; Electroconvulsive Therapy; Erythropoietin; Humans; Models, Biological; Thyroid Hormones

2015